Study guide

6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection

Key Takeaways Explain This Topic AI

USP <797> requires every CSP to be visually inspected after compounding and before release, checking its appearance, whether the label matches the order, and container closure integrity (leaks, cracks, seals).

A CSP that is not dispensed on the day it is made is inspected again immediately before release. Any defective CSP is rejected, labeled as rejected and segregated, and defects suggesting sterility or stability problems are investigated.

The familiar method of viewing each unit against black and white backgrounds for about 5 seconds each at 2,000–3,750 lux comes from USP <790> and <1790>, which also describe inspector qualification.

Container Closure Integrity Testing (CCIT) per USP <1207> confirms that a package keeps out microbes and gases. Deterministic methods such as vacuum decay, high-voltage leak detection and laser headspace analysis are preferred over probabilistic dye or microbial ingress tests.

Last updated: September 2026

Mandated Visual Inspection of Every CSP under USP <797>

USP <797> Section 12.1 requires every CSP to be visually inspected at the end of compounding, before release and dispensing. The check covers three things: the physical appearance (no visible particles or foreign matter, no discoloration or other defects), whether the label matches the prescription or order, and container closure integrity (no leaks, cracks or improper seals). A CSP that will not go out the same day is inspected again immediately before release, to catch precipitation, cloudiness or leakage that developed in storage. Destructive tests such as sterility and endotoxin use samples, but visual inspection covers every unit .

The practical technique below comes from USP <790> (visible particulates in injections) and its companion chapter <1790>:

Visual Inspection Protocol

Inspection Apparatus : USP <790> describes an illumination intensity of 2,000 to 3,750 lux at the inspection point, equipped with an anti-glare viewing screen with contrasting high-contrast black and white backgrounds .

Technique :

Remove external labels or tape that obscure the fluid pathway.

Gently swirl and invert the container (avoiding vigorous shaking that creates air bubbles mimicking particulates).

Hold the container against the black background for at least 5 seconds (optimizes detection of light-colored, reflective, or translucent particles like cellulose fibers, cotton lint, glass flakes, and protein precipitates).

Hold the container against the white background for at least 5 seconds (optimizes detection of dark, opaque particles like rubber cores, charred particles, and dark precipitates).

Defects Requiring Immediate Rejection : Presence of visible particulates, turbidity or cloudiness in a normally clear solution, color variation, container cracks, compromised crimp seals, or liquid leakage around the stopper or bag port.

Inspection Nuances for Diverse Container Systems

Large-Volume Parenterals (IV Infusion Bags) : In addition to optical clarity, flexible bags must undergo gentle physical compression testing to check for micro-tears along heat-welded seams and additive port junctions. Bags must be inverted to dislodge particulates adhering to interior bag walls.

Pre-filled Syringes : Must be inspected for particulate matter lodged between the rubber plunger ribs and the inner glass/plastic barrel surface, as well as checking the integrity of the tip cap seal.

Ophthalmic Dropper Containers : Semi-opaque or low-density polyethylene (LDPE) containers require high-intensity focused tangential lighting to ensure visibility through translucent container walls.

Container Closure Integrity Testing (CCIT) per USP <1207>

A container-closure system (e.g., glass vial with rubber stopper and aluminum crimp, plastic IV bag with port, or pre-filled syringe with tip cap) must maintain a continuous hermetic seal. If the seal fails, microbes can be drawn into the container via micro-capillary action during temperature cycling or handling.

USP <797> requires container closure integrity evaluation (per <1207>) for the containers of multiple-dose CSPs . USP's FAQ also lists closure integrity among the factors to weigh when assigning long BUDs. It is not, however, a separately listed Category 3 release test.

Deterministic vs. Probabilistic CCIT Methods

USP General Chapter <1207> classifies CCIT technologies into two categories, establishing a clear compendial preference for deterministic methodologies :

CCIT Category Method Description Primary Advantages Compendial Status

Deterministic Quantitative, non-destructive physicochemical measurement based on physical phenomena Highly reproducible, precise leak size quantification, objective pass/fail criteria Preferred by USP <1207>

Probabilistic Qualitative, outcome-based assays relying on random stochastic events (e.g., a microbe swimming through a tortuous path) Subject to high false-negative rates, destructive, qualitative Discouraged; secondary confirmation only

Primary Deterministic CCIT Methodologies

Vacuum Decay (ASTM F2338) : The test container is placed into a hermetically sealed evacuation chamber. A vacuum is pulled, and pressure change is monitored over time. A rise in chamber pressure indicates air or vapor leaking out of the container.

High-Voltage Leak Detection (HVLD) : The container is positioned between two high-voltage electrodes. If a micro-crack or pinhole exists in a glass vial or plastic syringe, electrical resistance drops dramatically as current arcs through the conductive liquid drug inside, signaling a leak.

Laser Headspace Analysis : A tunable diode laser beam passes through the headspace above a lyophilized or liquid vial, measuring oxygen concentration or water vapor pressure. Rising oxygen levels indicate atmospheric ingress through a compromised seal.

Visual Inspection Personnel Qualification & Defect Classification

Visual inspection reliability depends directly on human visual acuity, lighting geometry, and standardized operational fatigue controls:

Inspector Qualification & Vision Testing

Acuity Testing : USP <1790> describes periodic vision checks for inspectors, covering near visual acuity (with correction if needed) and color perception.

Qualification with Defect Sets : Inspectors are trained and qualified with test sets seeded with known defects, such as particle-containing units, cracked containers and underfilled units. Acceptance criteria are set in the facility's procedure.

Inspection Fatigue Controls : Detection drops with continuous inspection, so procedures limit continuous inspection time and build in breaks or task rotation.

Defect Classification Hierarchy (USP <790> & <1790>)

Defect Class Clinical Risk Level Batch Disposition Compendial Examples

Critical Defect Direct, life-threatening patient risk or complete sterility breach Immediate batch rejection; root-cause CAPA investigation Non-sterile particulates, glass shards, cracked ampuls, unseated rubber stoppers, open container seals

Major Defect Potential impairment of product efficacy or administration difficulty Batch quarantine pending Designated Person review Haze, a significant fill-volume error, crimp defects that may affect the seal

Minor Defect Cosmetic flaw without impact on product sterility or potency Unit rejection only; batch release permissible Crooked label, minor exterior glass scratch, superficial aluminum overcap scuff